| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Neoplasms | 110 | 2019 | 4557 | 5.010 |
Why?
|
| Hepatectomy | 58 | 2013 | 1011 | 3.610 |
Why?
|
| Hyperthermia, Induced | 20 | 2018 | 510 | 3.450 |
Why?
|
| Radio Waves | 12 | 2017 | 25 | 3.260 |
Why?
|
| Carcinoma, Hepatocellular | 50 | 2018 | 2027 | 3.080 |
Why?
|
| Catheter Ablation | 27 | 2016 | 620 | 2.870 |
Why?
|
| Gold | 14 | 2014 | 270 | 2.740 |
Why?
|
| Metal Nanoparticles | 13 | 2014 | 164 | 2.350 |
Why?
|
| Colorectal Neoplasms | 40 | 2013 | 3578 | 1.820 |
Why?
|
| Fullerenes | 6 | 2020 | 10 | 1.790 |
Why?
|
| Pancreatic Neoplasms | 22 | 2020 | 5061 | 1.500 |
Why?
|
| Bile Duct Neoplasms | 8 | 2017 | 493 | 1.160 |
Why?
|
| Nanoparticles | 7 | 2017 | 554 | 1.140 |
Why?
|
| Cholangiocarcinoma | 7 | 2017 | 493 | 1.090 |
Why?
|
| Bile Ducts, Intrahepatic | 6 | 2017 | 334 | 0.920 |
Why?
|
| Adenocarcinoma | 17 | 2018 | 7789 | 0.850 |
Why?
|
| Antibodies, Monoclonal | 14 | 2012 | 4367 | 0.840 |
Why?
|
| Deoxycytidine | 6 | 2017 | 1353 | 0.810 |
Why?
|
| Autophagy | 4 | 2020 | 927 | 0.810 |
Why?
|
| Gallbladder Neoplasms | 5 | 2018 | 245 | 0.780 |
Why?
|
| Cell Line, Tumor | 30 | 2020 | 14551 | 0.770 |
Why?
|
| Surgical Stapling | 2 | 2013 | 36 | 0.740 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2020 | 31 | 0.730 |
Why?
|
| Drug Delivery Systems | 7 | 2017 | 669 | 0.710 |
Why?
|
| Liver Neoplasms, Experimental | 4 | 2018 | 196 | 0.710 |
Why?
|
| Printing, Three-Dimensional | 2 | 2020 | 129 | 0.680 |
Why?
|
| Spheroids, Cellular | 2 | 2016 | 222 | 0.670 |
Why?
|
| Humans | 182 | 2021 | 261506 | 0.630 |
Why?
|
| Digestive System Surgical Procedures | 3 | 2010 | 275 | 0.620 |
Why?
|
| Hydrolases | 4 | 2010 | 123 | 0.610 |
Why?
|
| Mitochondria | 2 | 2014 | 1282 | 0.600 |
Why?
|
| Nanoconjugates | 2 | 2014 | 5 | 0.600 |
Why?
|
| Portal Vein | 12 | 2013 | 355 | 0.600 |
Why?
|
| Liver | 18 | 2021 | 2961 | 0.590 |
Why?
|
| Batch Cell Culture Techniques | 1 | 2016 | 8 | 0.590 |
Why?
|
| Cetuximab | 9 | 2014 | 472 | 0.580 |
Why?
|
| Neoplasms | 14 | 2021 | 15193 | 0.570 |
Why?
|
| Antineoplastic Agents | 23 | 2018 | 14289 | 0.550 |
Why?
|
| Diathermy | 2 | 2013 | 8 | 0.530 |
Why?
|
| Antibodies, Monoclonal, Humanized | 16 | 2014 | 3251 | 0.530 |
Why?
|
| Embolization, Therapeutic | 11 | 2013 | 551 | 0.530 |
Why?
|
| Tissue Scaffolds | 1 | 2016 | 135 | 0.530 |
Why?
|
| Hepatitis C, Chronic | 5 | 2013 | 451 | 0.500 |
Why?
|
| Tissue Engineering | 2 | 2016 | 269 | 0.500 |
Why?
|
| Hepatitis B, Chronic | 3 | 2013 | 137 | 0.500 |
Why?
|
| Nanotubes, Carbon | 3 | 2011 | 29 | 0.490 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2014 | 133 | 0.480 |
Why?
|
| Recombinational DNA Repair | 1 | 2014 | 79 | 0.480 |
Why?
|
| Survivors | 2 | 2010 | 1031 | 0.480 |
Why?
|
| Quantum Dots | 2 | 2011 | 30 | 0.470 |
Why?
|
| Colloids | 1 | 2013 | 34 | 0.470 |
Why?
|
| Endocytosis | 2 | 2012 | 225 | 0.470 |
Why?
|
| Cell Survival | 9 | 2018 | 3045 | 0.470 |
Why?
|
| Arginase | 2 | 2010 | 48 | 0.450 |
Why?
|
| Aged | 83 | 2018 | 70117 | 0.440 |
Why?
|
| Nanocapsules | 1 | 2012 | 28 | 0.440 |
Why?
|
| Microwaves | 2 | 2019 | 32 | 0.440 |
Why?
|
| Neoplasm Recurrence, Local | 22 | 2013 | 10035 | 0.440 |
Why?
|
| Postoperative Complications | 14 | 2013 | 5542 | 0.430 |
Why?
|
| Middle Aged | 93 | 2018 | 86204 | 0.430 |
Why?
|
| Survival Rate | 33 | 2018 | 12221 | 0.430 |
Why?
|
| Survival Analysis | 28 | 2019 | 9180 | 0.430 |
Why?
|
| Argininosuccinate Synthase | 2 | 2010 | 54 | 0.420 |
Why?
|
| Nuclear Pore | 1 | 2012 | 17 | 0.420 |
Why?
|
| Microscopy, Electron, Transmission | 6 | 2014 | 252 | 0.420 |
Why?
|
| Protein Denaturation | 1 | 2012 | 70 | 0.420 |
Why?
|
| Carbon | 1 | 2012 | 149 | 0.420 |
Why?
|
| Specialties, Surgical | 2 | 2017 | 137 | 0.410 |
Why?
|
| Cell Culture Techniques | 2 | 2016 | 598 | 0.400 |
Why?
|
| Chemotherapy, Adjuvant | 16 | 2017 | 3890 | 0.400 |
Why?
|
| Lactams, Macrocyclic | 1 | 2011 | 90 | 0.400 |
Why?
|
| Benzoquinones | 1 | 2011 | 108 | 0.400 |
Why?
|
| Female | 109 | 2019 | 141928 | 0.380 |
Why?
|
| Nanotechnology | 2 | 2009 | 137 | 0.380 |
Why?
|
| Treatment Outcome | 48 | 2018 | 32848 | 0.380 |
Why?
|
| Luciferases | 1 | 2012 | 445 | 0.380 |
Why?
|
| Ablation Techniques | 2 | 2014 | 148 | 0.370 |
Why?
|
| DNA Replication | 1 | 2014 | 744 | 0.370 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2011 | 196 | 0.370 |
Why?
|
| Blood Loss, Surgical | 4 | 2009 | 309 | 0.370 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2018 | 494 | 0.360 |
Why?
|
| Temperature | 2 | 2019 | 506 | 0.360 |
Why?
|
| Male | 95 | 2019 | 123000 | 0.360 |
Why?
|
| Nanomedicine | 1 | 2010 | 54 | 0.360 |
Why?
|
| Aged, 80 and over | 49 | 2018 | 29902 | 0.350 |
Why?
|
| Cell Proliferation | 5 | 2016 | 7226 | 0.350 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2014 | 1299 | 0.350 |
Why?
|
| Biliary Tract Neoplasms | 3 | 2009 | 167 | 0.350 |
Why?
|
| Neuroendocrine Tumors | 3 | 2011 | 634 | 0.350 |
Why?
|
| Adult | 75 | 2018 | 77950 | 0.340 |
Why?
|
| Caspase 3 | 1 | 2010 | 471 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2013 | 15862 | 0.330 |
Why?
|
| Retrospective Studies | 50 | 2018 | 37905 | 0.330 |
Why?
|
| DNA, Neoplasm | 1 | 2014 | 1910 | 0.330 |
Why?
|
| Immunoconjugates | 1 | 2012 | 279 | 0.330 |
Why?
|
| Mice, Inbred BALB C | 7 | 2017 | 2314 | 0.330 |
Why?
|
| Neoplasm Staging | 16 | 2018 | 13658 | 0.320 |
Why?
|
| Incineration | 1 | 2007 | 1 | 0.320 |
Why?
|
| Chi-Square Distribution | 11 | 2013 | 1323 | 0.310 |
Why?
|
| Hepatic Insufficiency | 4 | 2013 | 34 | 0.310 |
Why?
|
| Polyethylene Glycols | 6 | 2019 | 615 | 0.310 |
Why?
|
| Combined Modality Therapy | 19 | 2017 | 8865 | 0.300 |
Why?
|
| Surgical Procedures, Operative | 2 | 2009 | 383 | 0.300 |
Why?
|
| Tissue Distribution | 6 | 2017 | 875 | 0.300 |
Why?
|
| Protein Kinases | 1 | 2011 | 874 | 0.300 |
Why?
|
| Cisplatin | 3 | 2013 | 2432 | 0.290 |
Why?
|
| Animals | 28 | 2020 | 59536 | 0.290 |
Why?
|
| Tomography, Spiral Computed | 2 | 2007 | 133 | 0.280 |
Why?
|
| Drug Therapy | 2 | 2017 | 205 | 0.280 |
Why?
|
| Educational Measurement | 1 | 2009 | 362 | 0.280 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2017 | 1724 | 0.280 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2020 | 4757 | 0.280 |
Why?
|
| Liver Cirrhosis | 3 | 2013 | 941 | 0.260 |
Why?
|
| Chemoembolization, Therapeutic | 2 | 2010 | 181 | 0.260 |
Why?
|
| Hemostasis, Surgical | 1 | 2005 | 48 | 0.260 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 1258 | 0.260 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2014 | 7551 | 0.260 |
Why?
|
| Proportional Hazards Models | 15 | 2017 | 4988 | 0.260 |
Why?
|
| Neoplasm, Residual | 2 | 2010 | 1656 | 0.250 |
Why?
|
| Apoptosis | 7 | 2014 | 7591 | 0.250 |
Why?
|
| Laser Coagulation | 1 | 2005 | 136 | 0.250 |
Why?
|
| Cholecystectomy | 2 | 2018 | 107 | 0.250 |
Why?
|
| Liver Regeneration | 4 | 2013 | 134 | 0.250 |
Why?
|
| Mice | 18 | 2018 | 34495 | 0.240 |
Why?
|
| Patient Selection | 11 | 2013 | 2055 | 0.240 |
Why?
|
| Multivariate Analysis | 15 | 2017 | 4298 | 0.240 |
Why?
|
| Cryosurgery | 1 | 2005 | 167 | 0.240 |
Why?
|
| Prognosis | 28 | 2018 | 21713 | 0.230 |
Why?
|
| Risk Factors | 21 | 2016 | 17523 | 0.230 |
Why?
|
| Colonic Neoplasms | 7 | 2016 | 1390 | 0.230 |
Why?
|
| Time Factors | 19 | 2013 | 12926 | 0.230 |
Why?
|
| Flow Cytometry | 1 | 2009 | 3033 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2014 | 6207 | 0.220 |
Why?
|
| Liver Diseases | 4 | 2012 | 574 | 0.220 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2017 | 3821 | 0.220 |
Why?
|
| alpha-Fetoproteins | 4 | 2013 | 237 | 0.220 |
Why?
|
| Education, Medical, Graduate | 1 | 2009 | 671 | 0.220 |
Why?
|
| Follow-Up Studies | 19 | 2018 | 14889 | 0.220 |
Why?
|
| Mice, SCID | 4 | 2017 | 1869 | 0.220 |
Why?
|
| Reactive Oxygen Species | 2 | 2020 | 987 | 0.210 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2017 | 565 | 0.210 |
Why?
|
| Disease-Free Survival | 16 | 2014 | 10001 | 0.210 |
Why?
|
| DNA-Binding Proteins | 3 | 2014 | 4821 | 0.210 |
Why?
|
| Arginine | 5 | 2010 | 500 | 0.210 |
Why?
|
| Preoperative Care | 6 | 2013 | 1529 | 0.200 |
Why?
|
| Morbidity | 2 | 2013 | 397 | 0.200 |
Why?
|
| Antibodies | 4 | 2018 | 838 | 0.200 |
Why?
|
| Ultrasonography, Interventional | 3 | 2013 | 429 | 0.200 |
Why?
|
| Ethics, Medical | 1 | 2005 | 442 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 12 | 2013 | 4975 | 0.200 |
Why?
|
| Risk Assessment | 11 | 2013 | 6869 | 0.200 |
Why?
|
| Pancreatic Stellate Cells | 2 | 2018 | 76 | 0.200 |
Why?
|
| Cell Cycle | 3 | 2014 | 2084 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2014 | 5178 | 0.200 |
Why?
|
| Fluorescent Dyes | 3 | 2019 | 459 | 0.200 |
Why?
|
| Disease Models, Animal | 6 | 2018 | 7222 | 0.200 |
Why?
|
| Bioprinting | 1 | 2020 | 7 | 0.200 |
Why?
|
| ErbB Receptors | 4 | 2010 | 2295 | 0.200 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 2173 | 0.190 |
Why?
|
| Models, Biological | 4 | 2016 | 3254 | 0.190 |
Why?
|
| Diabetes Complications | 3 | 2012 | 305 | 0.190 |
Why?
|
| Mass Screening | 1 | 2009 | 1509 | 0.190 |
Why?
|
| Prospective Studies | 15 | 2013 | 12873 | 0.190 |
Why?
|
| Protein Corona | 1 | 2020 | 1 | 0.190 |
Why?
|
| Mice, Nude | 6 | 2017 | 4307 | 0.180 |
Why?
|
| Ultrasonography | 4 | 2013 | 1863 | 0.180 |
Why?
|
| Thermometry | 1 | 2019 | 8 | 0.180 |
Why?
|
| Heme Oxygenase-1 | 1 | 2020 | 54 | 0.180 |
Why?
|
| Surface Properties | 1 | 2020 | 180 | 0.180 |
Why?
|
| Neoplasm Metastasis | 5 | 2013 | 5112 | 0.170 |
Why?
|
| Boron Compounds | 1 | 2019 | 59 | 0.170 |
Why?
|
| Polymers | 1 | 2020 | 223 | 0.170 |
Why?
|
| Glycoconjugates | 1 | 2018 | 10 | 0.170 |
Why?
|
| Rabbits | 3 | 2010 | 957 | 0.170 |
Why?
|
| Fluorouracil | 10 | 2013 | 1944 | 0.170 |
Why?
|
| Solubility | 3 | 2017 | 242 | 0.170 |
Why?
|
| Intravital Microscopy | 2 | 2017 | 33 | 0.170 |
Why?
|
| Diethylnitrosamine | 1 | 2018 | 36 | 0.170 |
Why?
|
| Organoids | 1 | 2021 | 287 | 0.170 |
Why?
|
| Phenobarbital | 1 | 2018 | 48 | 0.170 |
Why?
|
| Postoperative Hemorrhage | 2 | 2012 | 162 | 0.170 |
Why?
|
| Neoplasm Proteins | 3 | 2016 | 3230 | 0.160 |
Why?
|
| Organoplatinum Compounds | 6 | 2012 | 702 | 0.160 |
Why?
|
| Photosensitizing Agents | 1 | 2018 | 71 | 0.160 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2020 | 278 | 0.160 |
Why?
|
| Venous Thromboembolism | 2 | 2013 | 335 | 0.160 |
Why?
|
| Oxidation-Reduction | 1 | 2020 | 717 | 0.160 |
Why?
|
| Water | 2 | 2017 | 361 | 0.160 |
Why?
|
| Ethanol | 2 | 2013 | 264 | 0.160 |
Why?
|
| Colectomy | 2 | 2012 | 288 | 0.150 |
Why?
|
| Palliative Care | 2 | 2008 | 2037 | 0.150 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2017 | 42 | 0.150 |
Why?
|
| Sensitivity and Specificity | 6 | 2010 | 4971 | 0.150 |
Why?
|
| Sarcoma | 2 | 2012 | 1725 | 0.150 |
Why?
|
| Intestines | 1 | 2021 | 686 | 0.140 |
Why?
|
| Microscopy, Fluorescence | 1 | 2019 | 769 | 0.140 |
Why?
|
| Adolescent | 19 | 2018 | 31252 | 0.140 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2016 | 98 | 0.140 |
Why?
|
| Neoplastic Stem Cells | 3 | 2017 | 1443 | 0.140 |
Why?
|
| Nanostructures | 1 | 2016 | 94 | 0.140 |
Why?
|
| Injections, Intramuscular | 3 | 2010 | 255 | 0.140 |
Why?
|
| Bevacizumab | 8 | 2012 | 938 | 0.130 |
Why?
|
| Hepacivirus | 2 | 2009 | 397 | 0.130 |
Why?
|
| Infusions, Intra-Arterial | 2 | 2007 | 171 | 0.130 |
Why?
|
| Polylysine | 1 | 2014 | 17 | 0.130 |
Why?
|
| Hepatic Artery | 2 | 2007 | 240 | 0.130 |
Why?
|
| Receptors, CXCR | 1 | 2014 | 19 | 0.130 |
Why?
|
| Signal Transduction | 3 | 2012 | 11965 | 0.130 |
Why?
|
| Hospitals | 1 | 2018 | 485 | 0.130 |
Why?
|
| Fluorescence | 2 | 2017 | 195 | 0.130 |
Why?
|
| Statistics, Nonparametric | 7 | 2013 | 980 | 0.130 |
Why?
|
| Fatty Liver | 2 | 2007 | 235 | 0.130 |
Why?
|
| Young Adult | 14 | 2018 | 21445 | 0.130 |
Why?
|
| Liver Transplantation | 5 | 2013 | 1112 | 0.130 |
Why?
|
| MRE11 Homologue Protein | 1 | 2014 | 39 | 0.130 |
Why?
|
| Mass Spectrometry | 3 | 2013 | 702 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 2 | 2017 | 1547 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2020 | 3552 | 0.120 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2012 | 489 | 0.120 |
Why?
|
| Exonucleases | 1 | 2014 | 51 | 0.120 |
Why?
|
| Breast Neoplasms | 8 | 2018 | 15694 | 0.120 |
Why?
|
| Camptothecin | 5 | 2012 | 517 | 0.120 |
Why?
|
| Stem Cells | 1 | 2021 | 1213 | 0.120 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 5159 | 0.120 |
Why?
|
| Necrosis | 2 | 2008 | 580 | 0.120 |
Why?
|
| Faculty, Medical | 1 | 2017 | 289 | 0.120 |
Why?
|
| Texas | 6 | 2013 | 6311 | 0.120 |
Why?
|
| Hyphae | 1 | 2013 | 44 | 0.120 |
Why?
|
| Cohort Studies | 10 | 2018 | 9244 | 0.120 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2013 | 39 | 0.120 |
Why?
|
| Silicon | 1 | 2013 | 48 | 0.120 |
Why?
|
| Decision Trees | 1 | 2013 | 178 | 0.120 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2015 | 221 | 0.110 |
Why?
|
| Case-Control Studies | 7 | 2012 | 6100 | 0.110 |
Why?
|
| von Hippel-Lindau Disease | 2 | 2006 | 115 | 0.110 |
Why?
|
| Blood Transfusion | 3 | 2013 | 583 | 0.110 |
Why?
|
| Rectal Neoplasms | 4 | 2006 | 1202 | 0.110 |
Why?
|
| Length of Stay | 4 | 2013 | 1900 | 0.110 |
Why?
|
| Aspergillus fumigatus | 1 | 2013 | 135 | 0.110 |
Why?
|
| Receptors, CXCR4 | 1 | 2014 | 269 | 0.110 |
Why?
|
| Stromal Cells | 1 | 2016 | 825 | 0.110 |
Why?
|
| Diabetes Mellitus | 2 | 2012 | 1054 | 0.110 |
Why?
|
| Injections | 1 | 2013 | 285 | 0.110 |
Why?
|
| Colon | 1 | 2016 | 670 | 0.110 |
Why?
|
| Bile Duct Diseases | 1 | 2012 | 45 | 0.110 |
Why?
|
| Lysosomes | 2 | 2012 | 347 | 0.110 |
Why?
|
| Thermometers | 1 | 2012 | 11 | 0.110 |
Why?
|
| United States | 14 | 2018 | 15433 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 2231 | 0.100 |
Why?
|
| Predictive Value of Tests | 5 | 2013 | 4892 | 0.100 |
Why?
|
| Cytidine Deaminase | 1 | 2011 | 83 | 0.100 |
Why?
|
| Cecal Neoplasms | 1 | 2011 | 7 | 0.100 |
Why?
|
| Luminescent Measurements | 1 | 2012 | 148 | 0.100 |
Why?
|
| GTP Phosphohydrolases | 1 | 2013 | 336 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 6 | 2016 | 5395 | 0.100 |
Why?
|
| Logistic Models | 7 | 2013 | 3441 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 630 | 0.100 |
Why?
|
| History, Ancient | 1 | 2010 | 68 | 0.100 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2010 | 551 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2009 | 1248 | 0.100 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 585 | 0.100 |
Why?
|
| Lymph Node Excision | 1 | 2018 | 1959 | 0.100 |
Why?
|
| Neoplasms, Experimental | 1 | 2014 | 750 | 0.100 |
Why?
|
| Benzenesulfonates | 1 | 2011 | 195 | 0.090 |
Why?
|
| DNA Mutational Analysis | 2 | 2013 | 2283 | 0.090 |
Why?
|
| Ki-67 Antigen | 2 | 2010 | 666 | 0.090 |
Why?
|
| Organ Size | 4 | 2013 | 690 | 0.090 |
Why?
|
| Particle Size | 1 | 2010 | 182 | 0.090 |
Why?
|
| Blood Cell Count | 1 | 2010 | 225 | 0.090 |
Why?
|
| Histocytochemistry | 1 | 2010 | 185 | 0.090 |
Why?
|
| Cell Differentiation | 1 | 2021 | 4078 | 0.090 |
Why?
|
| Cobalt | 1 | 2010 | 55 | 0.090 |
Why?
|
| Carcinoma, Lobular | 2 | 2012 | 611 | 0.090 |
Why?
|
| Enzyme Induction | 1 | 2010 | 249 | 0.090 |
Why?
|
| Immunotherapy | 2 | 2021 | 3341 | 0.090 |
Why?
|
| Collagenases | 1 | 2009 | 74 | 0.090 |
Why?
|
| Protein Engineering | 1 | 2010 | 100 | 0.090 |
Why?
|
| Trypsin | 1 | 2009 | 140 | 0.090 |
Why?
|
| Recombinant Proteins | 3 | 2013 | 2927 | 0.090 |
Why?
|
| Metastasectomy | 1 | 2012 | 200 | 0.090 |
Why?
|
| Niacinamide | 1 | 2011 | 421 | 0.090 |
Why?
|
| Manganese | 1 | 2010 | 80 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2010 | 275 | 0.090 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 573 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 945 | 0.090 |
Why?
|
| Telomerase | 2 | 2002 | 525 | 0.090 |
Why?
|
| ras Proteins | 1 | 2013 | 770 | 0.090 |
Why?
|
| Carcinoid Tumor | 1 | 2011 | 280 | 0.090 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2012 | 328 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2010 | 441 | 0.080 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2008 | 38 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2002 | 1555 | 0.080 |
Why?
|
| Patient Discharge | 1 | 2013 | 661 | 0.080 |
Why?
|
| Hepatitis B | 3 | 2008 | 258 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2010 | 574 | 0.080 |
Why?
|
| Phenylurea Compounds | 1 | 2011 | 580 | 0.080 |
Why?
|
| Probability | 3 | 2004 | 866 | 0.080 |
Why?
|
| Mutation | 6 | 2013 | 15179 | 0.080 |
Why?
|
| Biomarkers, Tumor | 5 | 2013 | 10331 | 0.080 |
Why?
|
| Lipids | 1 | 2012 | 644 | 0.080 |
Why?
|
| Italy | 2 | 2008 | 236 | 0.080 |
Why?
|
| Testicular Neoplasms | 1 | 2012 | 529 | 0.080 |
Why?
|
| Disease Progression | 4 | 2013 | 6682 | 0.080 |
Why?
|
| Thrombin | 1 | 2008 | 99 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2008 | 105 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 1162 | 0.080 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2012 | 1216 | 0.080 |
Why?
|
| Hypothyroidism | 1 | 2009 | 204 | 0.070 |
Why?
|
| Hemostasis | 1 | 2008 | 109 | 0.070 |
Why?
|
| Electrocoagulation | 1 | 2007 | 65 | 0.070 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2006 | 33 | 0.070 |
Why?
|
| Drug Administration Schedule | 4 | 2010 | 3472 | 0.070 |
Why?
|
| Incidence | 5 | 2013 | 5673 | 0.070 |
Why?
|
| Biopsy | 2 | 2013 | 3443 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2009 | 1008 | 0.070 |
Why?
|
| Optical Imaging | 2 | 2019 | 157 | 0.070 |
Why?
|
| Teaching | 1 | 2009 | 243 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2009 | 577 | 0.070 |
Why?
|
| Intra-Abdominal Fat | 1 | 2007 | 95 | 0.070 |
Why?
|
| Doxorubicin | 2 | 2013 | 3005 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2012 | 1130 | 0.070 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2006 | 209 | 0.070 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2011 | 600 | 0.070 |
Why?
|
| Computer Simulation | 3 | 2017 | 1529 | 0.070 |
Why?
|
| Digestive System Neoplasms | 1 | 2006 | 82 | 0.070 |
Why?
|
| Hepatitis C | 3 | 2008 | 524 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2013 | 4744 | 0.070 |
Why?
|
| Euthanasia, Passive | 1 | 2005 | 13 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 2216 | 0.070 |
Why?
|
| Abdominal Neoplasms | 1 | 2007 | 231 | 0.070 |
Why?
|
| Beneficence | 1 | 2005 | 87 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 3869 | 0.060 |
Why?
|
| Hepatic Veins | 1 | 2005 | 58 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2012 | 851 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 418 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2009 | 390 | 0.060 |
Why?
|
| Medical Futility | 1 | 2005 | 54 | 0.060 |
Why?
|
| Luminescent Proteins | 2 | 2002 | 289 | 0.060 |
Why?
|
| Social Justice | 1 | 2005 | 61 | 0.060 |
Why?
|
| Morals | 1 | 2005 | 70 | 0.060 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2011 | 716 | 0.060 |
Why?
|
| Pyridines | 1 | 2011 | 1244 | 0.060 |
Why?
|
| Leucovorin | 3 | 2012 | 332 | 0.060 |
Why?
|
| Monitoring, Intraoperative | 1 | 2006 | 264 | 0.060 |
Why?
|
| Advance Directives | 1 | 2005 | 88 | 0.060 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2004 | 115 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 2488 | 0.060 |
Why?
|
| Citrullinemia | 1 | 2004 | 19 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2021 | 5637 | 0.060 |
Why?
|
| Withholding Treatment | 1 | 2005 | 161 | 0.060 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2006 | 262 | 0.060 |
Why?
|
| Child | 7 | 2012 | 29154 | 0.060 |
Why?
|
| Swine | 2 | 2018 | 1541 | 0.060 |
Why?
|
| Odds Ratio | 3 | 2013 | 2316 | 0.060 |
Why?
|
| Eye Neoplasms | 1 | 2006 | 247 | 0.060 |
Why?
|
| Personal Autonomy | 1 | 2005 | 212 | 0.060 |
Why?
|
| Pheochromocytoma | 1 | 2006 | 281 | 0.060 |
Why?
|
| Reoperation | 3 | 2012 | 1382 | 0.060 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2006 | 297 | 0.060 |
Why?
|
| Anus Neoplasms | 1 | 2007 | 411 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2007 | 644 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2013 | 2819 | 0.050 |
Why?
|
| Registries | 2 | 2013 | 2170 | 0.050 |
Why?
|
| Biological Transport | 2 | 2017 | 597 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2013 | 2864 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2010 | 3719 | 0.050 |
Why?
|
| Nucleoside Deaminases | 1 | 2002 | 33 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 852 | 0.050 |
Why?
|
| Lymph Nodes | 3 | 2017 | 2967 | 0.050 |
Why?
|
| Lymphatic Metastasis | 5 | 2012 | 4844 | 0.050 |
Why?
|
| Adenoma, Islet Cell | 1 | 2002 | 27 | 0.050 |
Why?
|
| Glioblastoma | 1 | 2013 | 1797 | 0.050 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2005 | 252 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2011 | 1423 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2007 | 2594 | 0.050 |
Why?
|
| Antimalarials | 1 | 2002 | 55 | 0.050 |
Why?
|
| Databases, Factual | 4 | 2018 | 2218 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 310 | 0.050 |
Why?
|
| Anal Canal | 1 | 2003 | 238 | 0.050 |
Why?
|
| Enterohepatic Circulation | 1 | 2021 | 11 | 0.050 |
Why?
|
| Vena Cava, Inferior | 1 | 2003 | 190 | 0.050 |
Why?
|
| Lung Neoplasms | 6 | 2013 | 11538 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 6009 | 0.050 |
Why?
|
| General Surgery | 1 | 2005 | 326 | 0.050 |
Why?
|
| Remission Induction | 2 | 2010 | 3569 | 0.050 |
Why?
|
| src Homology Domains | 1 | 2002 | 124 | 0.050 |
Why?
|
| Protozoan Proteins | 1 | 2002 | 114 | 0.050 |
Why?
|
| Hypertrophy | 2 | 2013 | 162 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2012 | 1866 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2009 | 1270 | 0.050 |
Why?
|
| Membrane Glycoproteins | 2 | 2002 | 1073 | 0.050 |
Why?
|
| Viruses | 1 | 2002 | 159 | 0.050 |
Why?
|
| Prodrugs | 1 | 2002 | 217 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2002 | 311 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 8873 | 0.050 |
Why?
|
| Loss of Heterozygosity | 1 | 2002 | 602 | 0.050 |
Why?
|
| Hepatocytes | 1 | 2002 | 351 | 0.050 |
Why?
|
| Transplantation, Heterologous | 2 | 2013 | 1082 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2007 | 1996 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 1363 | 0.050 |
Why?
|
| Terminal Care | 1 | 2005 | 447 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2002 | 1538 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2011 | 1756 | 0.040 |
Why?
|
| Viscosity | 1 | 2019 | 47 | 0.040 |
Why?
|
| Smoking | 1 | 2008 | 2440 | 0.040 |
Why?
|
| Biosensing Techniques | 1 | 2019 | 75 | 0.040 |
Why?
|
| Laparoscopy | 2 | 2010 | 1225 | 0.040 |
Why?
|
| Body Temperature | 1 | 2019 | 158 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 1533 | 0.040 |
Why?
|
| Swine, Miniature | 1 | 2018 | 67 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 2018 | 197 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2004 | 4938 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2004 | 1301 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2002 | 3101 | 0.040 |
Why?
|
| Hernia, Ventral | 1 | 2020 | 159 | 0.040 |
Why?
|
| Photochemotherapy | 1 | 2018 | 96 | 0.040 |
Why?
|
| Stomach | 1 | 2021 | 387 | 0.040 |
Why?
|
| Dynamic Light Scattering | 1 | 2017 | 9 | 0.040 |
Why?
|
| Brain Neoplasms | 2 | 2013 | 4849 | 0.040 |
Why?
|
| Decision Making | 1 | 2005 | 1287 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2017 | 220 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 7702 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2021 | 785 | 0.040 |
Why?
|
| Carcinogens | 1 | 2018 | 384 | 0.040 |
Why?
|
| Bilirubin | 2 | 2009 | 221 | 0.040 |
Why?
|
| ROC Curve | 2 | 2012 | 1183 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2002 | 854 | 0.040 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2016 | 22 | 0.040 |
Why?
|
| Cell-Free System | 1 | 2016 | 150 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 4 | 2005 | 3981 | 0.040 |
Why?
|
| Cell Movement | 2 | 2015 | 2466 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2004 | 7548 | 0.030 |
Why?
|
| Inflammation | 2 | 2020 | 2522 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 4638 | 0.030 |
Why?
|
| Molecular Imaging | 1 | 2017 | 185 | 0.030 |
Why?
|
| Organogenesis | 1 | 2016 | 119 | 0.030 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2018 | 406 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2017 | 429 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2006 | 222 | 0.030 |
Why?
|
| Sex Factors | 2 | 2013 | 2139 | 0.030 |
Why?
|
| Brachytherapy | 1 | 2002 | 977 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 2403 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2018 | 1313 | 0.030 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2014 | 13 | 0.030 |
Why?
|
| Drug Stability | 1 | 2014 | 105 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 324 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2002 | 1616 | 0.030 |
Why?
|
| Drug Carriers | 1 | 2016 | 327 | 0.030 |
Why?
|
| Interferon-alpha | 2 | 2013 | 889 | 0.030 |
Why?
|
| Hospital Mortality | 2 | 2012 | 1274 | 0.030 |
Why?
|
| Kinetics | 1 | 2017 | 2049 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2014 | 155 | 0.030 |
Why?
|
| src-Family Kinases | 2 | 2011 | 478 | 0.030 |
Why?
|
| Capecitabine | 2 | 2006 | 388 | 0.030 |
Why?
|
| Carcinoma | 1 | 2006 | 2578 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2002 | 1823 | 0.030 |
Why?
|
| Electromagnetic Radiation | 1 | 2013 | 4 | 0.030 |
Why?
|
| Barbiturates | 1 | 2013 | 9 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 305 | 0.030 |
Why?
|
| Tetrazolium Salts | 1 | 2013 | 54 | 0.030 |
Why?
|
| Electricity | 1 | 2013 | 17 | 0.030 |
Why?
|
| Porosity | 1 | 2013 | 56 | 0.030 |
Why?
|
| Electromagnetic Fields | 1 | 2013 | 50 | 0.030 |
Why?
|
| Stomach Neoplasms | 1 | 2006 | 2278 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 2007 | 3168 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2013 | 136 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2013 | 114 | 0.030 |
Why?
|
| Microbial Viability | 1 | 2013 | 62 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2018 | 1620 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2013 | 226 | 0.030 |
Why?
|
| Transfusion Reaction | 1 | 2013 | 102 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 1062 | 0.030 |
Why?
|
| Isoxazoles | 1 | 2013 | 81 | 0.030 |
Why?
|
| Operative Time | 1 | 2013 | 217 | 0.030 |
Why?
|
| Ligation | 1 | 2013 | 193 | 0.030 |
Why?
|
| Melanoma | 2 | 2010 | 5317 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 1033 | 0.030 |
Why?
|
| Microspheres | 1 | 2013 | 210 | 0.030 |
Why?
|
| Cell Size | 1 | 2013 | 136 | 0.030 |
Why?
|
| Bile | 1 | 2012 | 81 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2013 | 281 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2011 | 2292 | 0.030 |
Why?
|
| Perfusion | 1 | 2013 | 293 | 0.030 |
Why?
|
| APOBEC-3G Deaminase | 1 | 2011 | 6 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 925 | 0.030 |
Why?
|
| Ligands | 1 | 2014 | 995 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2013 | 294 | 0.030 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 2 | 2002 | 205 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2007 | 3976 | 0.030 |
Why?
|
| Rats | 1 | 2020 | 6086 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2013 | 699 | 0.030 |
Why?
|
| Carcinogenicity Tests | 1 | 2011 | 70 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2013 | 250 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 5114 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2013 | 289 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 521 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2017 | 1048 | 0.020 |
Why?
|
| Administration, Oral | 2 | 2006 | 1544 | 0.020 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2011 | 103 | 0.020 |
Why?
|
| Urogenital Neoplasms | 1 | 2012 | 108 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 5437 | 0.020 |
Why?
|
| Dynamin II | 1 | 2010 | 5 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 1489 | 0.020 |
Why?
|
| Carbocyanines | 1 | 2010 | 41 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 256 | 0.020 |
Why?
|
| X-Ray Absorption Spectroscopy | 1 | 2010 | 3 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 58 | 0.020 |
Why?
|
| Sulfonylurea Compounds | 1 | 2010 | 32 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 1586 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2013 | 665 | 0.020 |
Why?
|
| Colorectal Surgery | 1 | 2010 | 32 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 2 | 2002 | 694 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 672 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2010 | 105 | 0.020 |
Why?
|
| Endosomes | 1 | 2010 | 109 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2016 | 1026 | 0.020 |
Why?
|
| Computational Biology | 1 | 2016 | 1271 | 0.020 |
Why?
|
| Golgi Apparatus | 1 | 2010 | 147 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2009 | 173 | 0.020 |
Why?
|
| Fibrinolytic Agents | 1 | 2012 | 324 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2002 | 621 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 4654 | 0.020 |
Why?
|
| Cocarcinogenesis | 1 | 2008 | 50 | 0.020 |
Why?
|
| Pancreas | 1 | 2012 | 718 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2009 | 176 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2011 | 1618 | 0.020 |
Why?
|
| Cytokines | 1 | 2018 | 2809 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 829 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 1519 | 0.020 |
Why?
|
| Gene Expression | 2 | 2010 | 3570 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2011 | 369 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 663 | 0.020 |
Why?
|
| Gels | 1 | 2008 | 105 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2007 | 191 | 0.020 |
Why?
|
| International Normalized Ratio | 1 | 2007 | 48 | 0.020 |
Why?
|
| Surface-Active Agents | 1 | 2006 | 41 | 0.020 |
Why?
|
| Sirolimus | 1 | 2011 | 814 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 2352 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 1678 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 1331 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1945 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2012 | 1987 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 1283 | 0.020 |
Why?
|
| Radiography | 1 | 2011 | 1904 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 1392 | 0.020 |
Why?
|
| Retreatment | 1 | 2007 | 452 | 0.020 |
Why?
|
| Metformin | 1 | 2010 | 378 | 0.020 |
Why?
|
| Celecoxib | 1 | 2006 | 200 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2009 | 551 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 3260 | 0.020 |
Why?
|
| Genes, bcl-2 | 1 | 2006 | 166 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 2005 | 159 | 0.020 |
Why?
|
| Pancreatic Diseases | 1 | 2006 | 108 | 0.020 |
Why?
|
| Adiposity | 1 | 2007 | 237 | 0.020 |
Why?
|
| Mastectomy | 1 | 2012 | 1534 | 0.020 |
Why?
|
| Dacarbazine | 1 | 2007 | 485 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 4917 | 0.020 |
Why?
|
| Cysts | 1 | 2006 | 197 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2009 | 636 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2013 | 2291 | 0.020 |
Why?
|
| Serologic Tests | 1 | 2004 | 137 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 2086 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2004 | 32 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2007 | 671 | 0.010 |
Why?
|
| Algorithms | 1 | 2015 | 3890 | 0.010 |
Why?
|
| Rosaniline Dyes | 1 | 2004 | 108 | 0.010 |
Why?
|
| Cancer Care Facilities | 1 | 2008 | 884 | 0.010 |
Why?
|
| Age Factors | 1 | 2013 | 5377 | 0.010 |
Why?
|
| Observer Variation | 1 | 2005 | 671 | 0.010 |
Why?
|
| Phenotype | 1 | 2015 | 6295 | 0.010 |
Why?
|
| France | 1 | 2003 | 108 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2010 | 1203 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2005 | 297 | 0.010 |
Why?
|
| Diaphragm | 1 | 2004 | 181 | 0.010 |
Why?
|
| Japan | 1 | 2003 | 227 | 0.010 |
Why?
|
| Keratins | 1 | 2004 | 330 | 0.010 |
Why?
|
| Recurrence | 1 | 2011 | 4758 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 660 | 0.010 |
Why?
|
| Flucytosine | 1 | 2002 | 30 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 334 | 0.010 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2002 | 10 | 0.010 |
Why?
|
| Cytosine Deaminase | 1 | 2002 | 39 | 0.010 |
Why?
|
| Pharmacogenetics | 1 | 2004 | 260 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2006 | 393 | 0.010 |
Why?
|
| Ligases | 1 | 2002 | 70 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 448 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 1165 | 0.010 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2002 | 107 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 568 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2011 | 6150 | 0.010 |
Why?
|
| Folic Acid | 1 | 2003 | 349 | 0.010 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2002 | 155 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 2002 | 271 | 0.010 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2004 | 500 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 2803 | 0.010 |
Why?
|
| Transgenes | 1 | 2002 | 557 | 0.010 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2002 | 363 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 1382 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2002 | 716 | 0.010 |
Why?
|
| Biomarkers | 1 | 2010 | 5047 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2006 | 2203 | 0.010 |
Why?
|
| Graft Survival | 1 | 2002 | 1062 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 1764 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 2489 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 862 | 0.010 |
Why?
|
| Pedigree | 1 | 2002 | 1890 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2011 | 2947 | 0.010 |
Why?
|
| Pain | 1 | 2006 | 1658 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 2307 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2006 | 1471 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2006 | 1823 | 0.010 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2004 | 1415 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2002 | 1694 | 0.010 |
Why?
|
| Radiotherapy, Conformal | 1 | 2002 | 902 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2002 | 1459 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2002 | 1152 | 0.010 |
Why?
|
| Obesity | 1 | 2009 | 2884 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2004 | 3842 | 0.010 |
Why?
|
| DNA | 1 | 2002 | 2693 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2009 | 16273 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2002 | 2359 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2003 | 2576 | 0.010 |
Why?
|